These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 18381625

  • 1. Synthesis and in vivo studies of carbohydrate-based vaccines against group A streptococcus.
    Simerska P, Abdel-Aal AB, Fujita Y, Batzloff MR, Good MF, Toth I.
    Biopolymers; 2008; 90(5):611-6. PubMed ID: 18381625
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C, Sun HK, Ho MF, Dyer J, Horváth A, Toth I, Good MF.
    J Infect Dis; 2006 Aug 01; 194(3):316-24. PubMed ID: 16826479
    [Abstract] [Full Text] [Related]

  • 4. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.
    Yoonim N, Olive C, Pruksachatkunakorn C, Pruksakorn S.
    BMC Microbiol; 2006 Aug 09; 6():71. PubMed ID: 16895610
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Method for the synthesis of highly pure vaccines using the lipid core peptide system.
    Moyle PM, Olive C, Good MF, Toth I.
    J Pept Sci; 2006 Dec 09; 12(12):800-7. PubMed ID: 17131293
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.
    Zaman M, Abdel-Aal AB, Fujita Y, Ziora ZM, Batzloff MR, Good MF, Toth I.
    J Med Chem; 2012 Oct 11; 55(19):8515-23. PubMed ID: 22974133
    [Abstract] [Full Text] [Related]

  • 13. M protein conserved region antibodies opsonise multiple strains of Streptococcus pyogenes with sequence variations in C-repeats.
    Vohra H, Dey N, Gupta S, Sharma AK, Kumar R, McMillan D, Good MF.
    Res Microbiol; 2005 May 11; 156(4):575-82. PubMed ID: 15862457
    [Abstract] [Full Text] [Related]

  • 14. Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage.
    Horváth A, Olive C, Karpati L, Sun HK, Good M, Toth I.
    J Med Chem; 2004 Jul 29; 47(16):4100-4. PubMed ID: 15267249
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates.
    Abdel-Aal AB, Batzloff MR, Fujita Y, Barozzi N, Faria A, Simerska P, Moyle PM, Good MF, Toth I.
    J Med Chem; 2008 Jan 10; 51(1):167-72. PubMed ID: 18072728
    [Abstract] [Full Text] [Related]

  • 17. Synthesis of a Streptococcus pyogenes vaccine candidate based on the M protein PL1 epitope.
    Simerska P, Lu H, Toth I.
    Bioorg Med Chem Lett; 2009 Feb 01; 19(3):821-4. PubMed ID: 19097790
    [Abstract] [Full Text] [Related]

  • 18. Comparative in silico analysis of two vaccine candidates for group A streptococcus predicts that they both may have similar safety profiles.
    Shaila MS, Nayak R, Prakash SS, Georgousakis M, Brandt E, McMillan DJ, Batzloff MR, Pruksakorn S, Good MF, Sriprakash KS.
    Vaccine; 2007 May 04; 25(18):3567-73. PubMed ID: 17293014
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.